RT Journal Article
SR Electronic
T1 Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3185
OP 3188
VO 34
IS 6
A1 MELISSA BERSANELLI
A1 MARCELLO TISEO
A1 FABRIZIO ARTIOLI
A1 LEONARDO LUCCHI
A1 ANDREA ARDIZZONI
YR 2014
UL http://ar.iiarjournals.org/content/34/6/3185.abstract
AB Renal failure in cancer patients is not a rare clinical condition and often contraindicates anticancer drug treatment; moreover, chemotherapeutic drugs are frequently identified as possible iatrogenic cause of renal failure. Molecular therapies, when appropriate, could represent a therapeutic option for cancer patients with severe renal disease, but the lack of knowledge in this field, at present, limits their use in patients undergoing dialysis. Herein we describe a case, at our knowledge the first reported, of a patient with advanced lung adenocarcinoma on maintenance hemodialysis treated with gefitinib and then with afatinib; we also reviewed the literature on epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) used in NSCLC patients with concomitant renal impairment.